These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 16687087)

  • 1. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
    Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
    Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction of dendritic cells from intra-operative lost blood and their effects on CIK against liver cancer cells in vitro].
    DU Z; Zhao XL; Gao YT; Wu CX; Wang YJ; Zhu ZY; Sun Q; Fang SC
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):759-63. PubMed ID: 19173806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes].
    Sun Y; Chen J; Cai P; Hu YH; Zhong GC; Feng HZ; Min M; Li S; Zhang C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):219-23. PubMed ID: 20137151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
    Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
    Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma.
    Zhao X; Zhang Z; Li H; Huang J; Yang S; Xie T; Huang L; Yue D; Xu L; Wang L; Zhang W; Zhang Y
    Cancer Lett; 2015 Jul; 362(2):192-8. PubMed ID: 25843292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
    Gao J; Chen M; Peng ML; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
    Sievers E; Albers P; Schmidt-Wolf IG; Märten A
    J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
    Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.